Dimension Inx Announces Issuance of “Self-gelling” Patent that Enables Novel Implantable and Injectable Materials

April 2, 2024 - We are excited to announce the recent issuance of Dimension Inx’s newest patent, US Patent No. 11,944,726, which covers composition and manufacture of a novel, hydrogel-containing material family that is shelf-stable in its dry form, yet gels to form an interconnected gel network when hydrated, i.e., it’s “self-gelling”.

This material family is unique because it enables the creation of 3D-printable, gel-laden, nanostructured implants and injectables that combine the biofunctional nano- and microstructure characteristic of our biomaterials with the additional biological benefits of hydrogels. Our self-gelling material family offers an innovative and simple approach for the delivery, localization, and stabilization of one or more hydrogels in vivo. It’s yet another demonstration of our platform’s unique capabilities - simultaneous control of material architecture and composition to promote cell viability and tissue engraftment while maintaining manufacturability and user-friendliness.

Thanks to our co-founder, Adam E. Jakus, PhD, who strategically developed this technology in response to existing limitations in the delivery and localization of hydrogel-based biomaterials. This work further expands upon an expansive patent portfolio at Dimension Inx beyond implantable materials to include injectables – all of which are dedicated to the design and manufacture of advanced biomaterials for tissuetherapeutic products that rebuild healthy tissues and restore organ function.

To learn more about our technology or if you're interested in joining a motivated team developing the next generation of regenerative therapeutics, please visit https://www.dimensioninx.com/.

+ About Dimension Inx

Dimension Inx is a regenerative therapeutics company. We design, develop, and manufacture products that restore tissue and organ function. Our materials-centric approach enables biofunctionality without compromising manufacturability. We precisely tune our biomaterials to create clinical solutions not otherwise possible. We work shoulder-to-shoulder with biotech partners to help solve their most challenging materials problems, and internally develop regenerative products for therapeutic applications with high unmet clinical need.

Dimension Inx is proudly based in Chicago, Illinois.  To learn more about our team and our technology, please visit www.dimensioninx.com.

Media Contact: Cole Johnson, VP Strategic Growth, Dimension Inx, colejohnson@dimensioninx.com